Research Topics
| George P KimSummaryAffiliation: Mayo Clinic Country: USA Publications
| Collaborators
|
Detail Information
Publications
Treatment options for hepatobiliary and pancreatic cancerSteven R Alberts
Division of Medical Oncology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Mayo Clin Proc 82:628-37. 2007..For pancreatic cancer, surgery, radiation, and systemic therapy all have potential roles. This review provides an updated summary of diagnosis and assessment together with treatment options for this group of cancers...- Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative StudyGeorge P Kim
National Surgical Adjuvant Breast and Bowel Project NSABP Operations and Biostatistical Centers, Mayo Clinic, Jacksonville, FL 32224, USA
J Clin Oncol 25:767-72. 2007..The role of high-degree microsatellite instability (MSI-H) as a marker to predict benefit from adjuvant chemotherapy remains unclear... - Oxaliplatin in the treatment of colorectal cancerGeorge P Kim
Mayo Clinic, 4500 San Pablo Road, Jacksonville, Florida 32082, USA
Expert Opin Drug Metab Toxicol 3:281-94. 2007..Future challenges with the use of oxaliplatin include defining strategies to optimize its use while avoiding treatment-limiting neurotoxicity and identification of markers predictive of response... - An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinomaGeorge P Kim
Mayo Clinic Florida, Jacksonville, FL, USA
Invest New Drugs 30:387-94. 2012..This phase II study evaluated the activity and tolerability of bortezomib in unresectable hepatocellular carcinoma (HCC) patients... - Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841George P Kim
Mayo Clinic Jacksonville, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
J Clin Oncol 27:2848-54. 2009..Cross-over to the other treatment on disease progression was mandated... - Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trialsFrank A Sinicrope
North Central Cancer Treatment Group, Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 30:406-12. 2012..Although the importance of obesity in colon cancer risk and outcome is recognized, the association of body mass index (BMI) with DNA mismatch repair (MMR) status is unknown... - Retransplantation for donor-derived neuroendocrine tumorRehana Begum
Department of Transplant, Mayo Clinic, Jacksonville, FL 32224, USA
Liver Transpl 17:83-7. 2011..The high grade nature of the NET was the most important determinant of prognosis in this case. Our experience suggests that retransplantation for donor-derived NET should only be considered when tumor biology is favorable... - Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005)Michele M Corsini
Department of Radiation Oncology the Division of Gastroenterologic and General Surgery, Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 26:3511-6. 2008..To determine prognostic factors and impact of adjuvant chemotherapy (CT) and radiotherapy (RT) on overall survival (OS) after resection of pancreatic adenocarcinoma... - Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathwayGeorge P Kim
Division of Hematology/Oncology, Mayo Clinic Jacksonville, FL, USA
Clin Colorectal Cancer 5:S89-97. 2005..This article reviews the impact of EGF receptor inhibitors on improving survival in CRC when combined with oxaliplatin-containing regimens... - Pemetrexed and oxaliplatin for metastatic colorectal cancer: results of a phase I Mayo Cancer Center Research Consortium trial, MC0248Steven R Alberts
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
Clin Colorectal Cancer 6:572-7. 2007..A phase I trial was performed to establish the maximum tolerated dose (MTD) of pemetrexed and oxaliplatin when B(12) and folate supplementation is used... - Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trialCharles L Loprinzi
Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 56301, USA
Cancer 104:176-82. 2005..Secondary research goals were to evaluate toxicities, tolerability, and quality of life associated with this shark cartilage product... - Obesity adversely affects survival in pancreatic cancer patientsRobert R McWilliams
Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
Cancer 116:5054-62. 2010..The authors assessed the association of BMI with survival in a sample of pancreatic cancer patients and used epidemiologic and clinical information to understand the contribution of diabetes and hyperglycemia... - Impact of neoadjuvant chemoradiation on the tumor burden before liver transplantation for unresectable cholangiocarcinomaChakri Panjala
Divisions of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL
Liver Transpl 18:594-601. 2012..More effective chemoradiation regimens for reducing the tumor burden and the appropriate timing of LT after neoadjuvant chemoradiation require further research. Liver Transpl, 2012. © 2012 AASLD...